Register for free
Recent Quotes
My Watchlist
Indicators
Business Insurance Index
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Biohaven Ltd. Common Shares (NY:BHVN)

13.88 -0.81 (-5.51%)
Official Closing Price Updated: 7:00 PM EDT, Oct 23, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Biohaven Ltd. Common Shares

< Previous 1 2 3 4 5 6 7 8 9
...
15 16 Next >
Top US Stock Gainers and Losers for the Oct. 22, 2026 Session ↗
Via Chartmill
Top Gainers and Losers in Today's US Session ↗
Via Chartmill
Gap-Up and Gap-Down Stocks: US Movers on October 22, 2026 ↗
Via Chartmill
Premarket movers Oct. 22: double-digit gainers and losers ↗
Via Chartmill
Biohaven Ltd. (NYSE:BHVN) Posts Narrower-Than-Expected Q4 2025 Loss Amid Clinical Progress ↗
Via Chartmill
These stocks that are showing activity before the opening bell on Thursday. ↗
Via Chartmill
News headline image
Why Biohaven Stock Was Rocking the Market This Week ↗
It signed a collaboration and licensing deal potentially worth $795 million. 
Via The Motley Fool
News headline image
12 Health Care Stocks Moving In Wednesday's Intraday Session ↗
Gainers Biohaven (NYSE:BHVN) shares increased by 16.5% to $16.75 during Wednesday's regular session. The market value of their outstanding shares is at $2.1 billion. SCYNEXIS (NASDAQ:SCYX) stock... 
Via Benzinga
News headline image
Why Biohaven Stock Crushed it on Monday ↗
The biotech was boosted by an analyst's initiation of coverage. 
Via The Motley Fool
News headline image
Biohaven Stock Down 70% but One Fund's New $6 Million Bet Signals Turnaround Potential ↗
This clinical-stage biotech focuses on developing therapies for neurological and immunoscience disorders. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
This $8.9 Million Buy Targets a Stock Down 68% With $322 Million in Cash ↗
Biohaven develops clinical-stage therapies for neurological and immunoscience disorders, with no commercialized products to date. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
XENE Stock Rallies 50% On Epilepsy Trial Data, But One Analyst Thinks Rival Biohaven Still Has ‘Room To Differentiate’ ↗
Xenon said that the late-stage study met its primary endpoint of median percent change from baseline in monthly FOS frequency to week 12 in both the 25 mg and 15 mg dose groups compared to placebo. 
Via Stocktwits
News headline image
SSR Mining Stock Up 180% as New $5 Million Stake Signals Gold Conviction ↗
SSR Mining runs a diversified portfolio of gold, silver, and base metal mines across four continents with a vertically integrated model. 
Via The Motley Fool
Topics ETFs Regulatory Compliance
News headline image
Nuvation Bio Stock Up 130% This Past Year as One Fund Discloses $3 Million Buy ↗
This clinical-stage biotech advances oncology therapies with a pipeline of novel small molecule inhibitors for hard-to-treat cancers. 
Via The Motley Fool
Topics Regulatory Compliance
Wondering what's happening in today's after-hours session? ↗
Via Chartmill
News headline image
Biohaven Ltd. (BHVN): A High-Stakes Clinical Crossroad in Neuroscience and Immunology
As of December 26, 2025, Biohaven Ltd. (NYSE: BHVN) finds itself at a critical juncture. Once the darling of the biotech sector following a staggering $11.6 billion acquisition of its migraine... 
Via PredictStreet
Topics Economy Intellectual Property
News headline image
Stay updated with the stocks that are on the move in today's pre-market session. ↗
Discover the top movers in Friday's pre-market session and stay informed about market dynamics. 
Via Chartmill
News headline image
Biohaven’s Phase II Depression Trial Falls Short, But Analysts Downplay Impact – Wall Street Looks Ahead To Epilepsy Data ↗
William Blair expected challenges with the depression study, given difficulties in executing trials and the prevalence of placebo effects. 
Via Stocktwits
Topics Artificial Intelligence
News headline image
Thursday's after hours session: top gainers and losers ↗
After the closing bell on Thursday, let's take a glimpse of the US markets and explore the top gainers and losers in today's after-hours session. 
Via Chartmill
News headline image
Which stocks are moving after the closing bell on Wednesday? ↗
As the regular session of the US market concludes on Wednesday, let's get an insight into the after-hours session and identify the stocks leading the pack in terms of gains and losses. 
Via Chartmill
News headline image
Biohaven Stock Slumps After Hours As Failed Depression Study Adds To A Brutal 2025 — Retail Eyes Epilepsy And Obesity Catalysts ↗
The company said that no reduction in depressive symptoms were observed in the BHV-7000 trial over six weeks as compared with placebo. 
Via Stocktwits
News headline image
Biohaven Insiders Bet $33 Million on a Turnaround ↗
Via MarketBeat
News headline image
Biohaven's Chief Accounting Officer Scooped Up 17,000 Shares. Is the Stock a Buy? ↗
The Chief Accounting Officer added to his more than 85,000 shares held. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Is Teladoc Stock a Buy After Oracle Investment Management Upped Its Stake? ↗
The investment company displayed confidence in Teladoc's growth potential by expanding its holdings in the stock. 
Via The Motley Fool
News headline image
FLEX LNG, Biohaven And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session ↗
 
Via Benzinga
News headline image
Why LightPath Technologies Shares Are Trading Higher By 7%; Here Are 20 Stocks Moving Premarket ↗
 
Via Benzinga
News headline image
These stocks are moving in today's session ↗
Curious about what's happening in today's session? Check out the latest stock movements and price changes. 
Via Chartmill
News headline image
Biohaven Stock Hits 52-Week Low, Cuts R&D Spending After FDA Rejection ↗
Biohaven stock plunged after the FDA rejected Vyglxia for spinocerebellar ataxia, prompting major R&D cuts and a William Blair downgrade. 
Via Benzinga
News headline image
Keep an eye on the top gainers and losers in Wednesday's session. ↗
Curious to know what's happening on the US markets in the middle of the day on Wednesday? Join us as we explore the top gainers and losers in today's session. 
Via Chartmill
News headline image
12 Health Care Stocks Moving In Wednesday's Intraday Session ↗
 
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 9
...
15 16 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Business Insurance is a singular, authoritative news and information source for executives focused upon risk management, risk transfer and risk financing.

Never miss important news. Subscribe to our newsletter.
Register for free

Information

Copyright 2024. BUSINESS INSURANCE HOLDINGS